NEW YORK; Nov. 9, 2021 – Accenture (NYSE: ACN) has made a strategic investment, through
Accenture Ventures, in
Geneyx Genomex Ltd. (Geneyx), an Israel-based developer of genomic analysis and interpretation software. Geneyx helps improve patient outcomes associated with hereditary and rare diseases by providing disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and pharmaceutical organizations.